Pharmacokinetics of the individual enantiomers of vigabatrin in neonates with uncontrolled seizures.

Br J Clin Pharmacol

Pharmacologie Clinique Périnatale et Pédiatrique, Université René Descartes, Hôpital Saint-Vincent de Paul (Assistance Publique-Hôpitaux de Paris, France.

Published: December 1996

The antiepileptic drug vigabatrin (VGB) is a selective irreversible inhibitor of GABA-transaminase. It is administered as a racemic R(-), S(+) mixture, but the pharmacological activity of vigabatrin resides in the S(+) enantiomer and the R(-) enantiomer is inactive. The pharmacokinetic parameters of the two enantiomers have been studied after administration of a single oral 125 mg dose of the racemate to six neonates. The mean values of Cmax and AUC of the S(+) enantiomer were significantly lower (Cmax: 14.0 +/- 4.3 mg l-1; AUC: 143 +/- 44 mg l-1 h) than those of the R(-) enantiomer (Cmax: 34.1 +/- 9.5 mg l-1; AUC: 231 +/- 88 mg l-1 h), whereas no significant difference in the time to reach Cmax (S(+): 2.1 +/- 1.1 h; R(-): 2.2 +/- 1 h) was observed between the two enantiomers. During chronic administration (125 mg twice daily over 4 days), there was no evidence of accumulation of either enantiomer.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2042707PMC
http://dx.doi.org/10.1046/j.1365-2125.1996.00495.xDOI Listing

Publication Analysis

Top Keywords

+/- l-1
16
l-1 auc
8
+/-
6
enantiomer
5
pharmacokinetics individual
4
individual enantiomers
4
enantiomers vigabatrin
4
vigabatrin neonates
4
neonates uncontrolled
4
uncontrolled seizures
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!